Vi Antigen from Salmonella Typhosa and Immunity Against Typhoid Fever. I. Isolation and Immunologic Properties in Animals

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1974 Feb 1

PMID 4205947

Citations 10

Authors

K H Wong

J C Feeley

R S Northrup

M E Forlines

Affiliations

Soon will be listed here.

Abstract

The role of Vi antigen in human immunity against typhoid fever has been debated for decades. Circumstantial evidence indicates that Vi antigen may play a role in pathogenicity and immunity. A Vi preparation was isolated from Salmonella typhosa, the causative organism in human typhoid fever, by a mild precipitation method. It was significantly more potent in animal studies than preparations from Citrobacter used in the past for human study and less toxic than conventional typhoid vaccines. With this antigen, the role of Vi antigen in human protection is now being investigated.

Citing Articles

Vi Capsular Polysaccharide Produced by Recombinant Serovar Paratyphi A Confers Immunoprotection against Infection by Serovar Typhi.

Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X Front Cell Infect Microbiol. 2017; 7:135.

PMID: 28484685 PMC: 5401900. DOI: 10.3389/fcimb.2017.00135.

Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.

Kantele A, Pakkanen S, Karttunen R, Kantele J PLoS One. 2013; 8(4):e60583.

PMID: 23593253 PMC: 3620468. DOI: 10.1371/journal.pone.0060583.

Typhoid fever & vaccine development: a partially answered question.

Marathe S, Lahiri A, Negi V, Chakravortty D Indian J Med Res. 2012; 135:161-9.

PMID: 22446857 PMC: 3336846.

Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.

Wang J, Noriega F, Galen J, Barry E, Levine M Infect Immun. 2000; 68(8):4647-52.

PMID: 10899868 PMC: 98400. DOI: 10.1128/IAI.68.8.4647-4652.2000.

Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi.

Nolan C, Feeley J, WHITE Jr P, Hambie E, Brown S, Wong K J Clin Microbiol. 1980; 12(1):22-6.

PMID: 7419698 PMC: 273512. DOI: 10.1128/jcm.12.1.22-26.1980.

References

Wong K, Miller C, Feeley J, Chan Y . Determination of endotoxicity in bacterial vaccines. Appl Microbiol. 1973; 25(3):403-7. PMC: 380818. DOI: 10.1128/am.25.3.403-407.1973. View

Jones G, Rutter J . Role of the K88 antigen in the pathogenesis of neonatal diarrhea caused by Escherichia coli in piglets. Infect Immun. 1972; 6(6):918-27. PMC: 419313. DOI: 10.1128/iai.6.6.918-927.1972. View

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View

Tully J, Gaines S . H antigen of Salmonella typhosa. J Bacteriol. 1961; 81:924-32. PMC: 314761. DOI: 10.1128/jb.81.6.924-932.1961. View

Venneman M, BERRY L . Cell-mediated resistance induced with immunogenic preparations of Salmonella typhimurium. Infect Immun. 1971; 4(4):381-7. PMC: 416317. DOI: 10.1128/iai.4.4.381-387.1971. View

Tully J, Gaines S, TIGER TT W . Studies on infection and immunity in experimental typhoid fever. IV. Role of H antigen in protection. J Infect Dis. 1963; 112:118-24. DOI: 10.1093/infdis/112.2.118. View

WEBSTER M, Landy M, Freeman M . Studies on Vi antigen. II. Purification of Vi antigen from Escherichia coli 5395/38. J Immunol. 1952; 69(2):135-42. View

Williams R, Gibbons R . Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal. Science. 1972; 177(4050):697-9. DOI: 10.1126/science.177.4050.697. View

Wong K, Pickett M, Froman S . Antigens of mycobacterial cell walls. Infect Immun. 1970; 1(4):400-7. PMC: 415912. DOI: 10.1128/iai.1.4.400-407.1970. View

10.

BAKER E, Whiteside R, Basch R, Derow M . The VI antigens of the Enterobacteriaceae. I. Purification and chemical properties. J Immunol. 1959; 83:680-96. View

11.

Hornick R, GREISMAN S, WOODWARD T, DuPont H, Dawkins A, Snyder M . Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 1970; 283(13):686-91. DOI: 10.1056/NEJM197009242831306. View

12.

Landy M . Enhancement of the immunogenicity of typhoid vaccine by retention of the V1 antigen. Am J Hyg. 1953; 58(2):148-64. DOI: 10.1093/oxfordjournals.aje.a119596. View

13.

Wong K, Feeley J . Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol. 1972; 24(4):628-33. PMC: 380626. DOI: 10.1128/am.24.4.628-633.1972. View

14.

CVJETANOVIC B, Uemura K . THE PRESENT STATUS OF FIELD AND LABORATORY STUDIES OF TYPHOID AND PARATYPHOID VACCINES WITH SPECIAL REFERENCE TO STUDIES SPONSORED BY WORLD HEALTH ORGANIZATION. Bull World Health Organ. 1965; 32:29-36. PMC: 2555191. View

15.

Landy M, Lamb E . Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc Soc Exp Biol Med. 1953; 82(4):593-8. DOI: 10.3181/00379727-82-20188. View

16.

Wong K, Feeley J, Pittman M . Effect of a Vi-degrading enzyme on potency of typhoid vaccines in mice. J Infect Dis. 1972; 125(4):360-6. DOI: 10.1093/infdis/125.4.360. View

17.

Pittman M, Bohner H . Laboratory assays of different types of field trial typhoid vaccines and relationship to efficacy in man. J Bacteriol. 1966; 91(5):1713-23. PMC: 316112. DOI: 10.1128/jb.91.5.1713-1723.1966. View